Efficacy of Dexmedetomidine as an Adjuvant to Quadratus Lumborum Block
- Disease/Condition
- Pain, Postoperative
- Study type
- Observational
- Primary sponsor
- Istanbul University - Cerrahpasa (IUC)
- Location
- Istanbul, Turkey
- Phase
- N/A
- Start date
- Dec 01, 2022
- End date
- Apr 01, 2023
- Enrollment
- 60 participants
the time to first rescue analgesic requirement
This prospective double blinded study will be conducted over 60 pediatric patients ASA
 (American Association of Anesthesiologists) I and II between the age of 1-7 years old, who
 will be scheduled for unilateral groin surgery. Patients will be randomly allocated into 3
 study groups: Control group that only received local anesthetics ( bupivacaine) Group II
 bupivacaine with the dexmetedomidine ( 0,5mcg/kg ) and group III bupivacaine with the
 dexmedetomidine (1mcg/kg).Patients in all groups will receive quadratus lumborum block.
 
 Bradycardia, hypotension, atropine, and bolus fluid infusion requirements will be recorded.
 When there was up to a 30% decrease in basal mean blood pressure, a crystalloid infusion
 bolus will be given at 10 ml/kg. When bradycardia occurred , atropine will be given at a dose
 of 0.02 mg/kg. Patients will be followed up in the postoperative recovery unit for the first
 2 hours, and then in the ward. The RAMSEY sedation scale and WATCHA agitation scale were
 evaluated at 5, 15, 30, and 60 minutes in the postoperative recovery unit. Nausea, vomiting,
 and other side effects were recorded if present.
 
 Time to first analgesic requirement ( primary outcome) , FLACC Scale scores will be recorded
 within 24h postoperatively, total dose of analgesic consumption, incidence of postoperative
 complications as hypotension, bradycardia, vomiting, pruritis and respiratory depression will
 be recorded.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05979376
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05979376 through Pure Global AI's free database. This phase not specified trial is sponsored by Istanbul University - Cerrahpasa (IUC) and is currently Completed. The study focuses on Pain, Postoperative. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.